Changes in laboratory results for cancer patients treated with interleukin-2

C. M. Huang, Ronald J. Elin, Mark Ruddel, Clara Sliva, Micahel T. Lotze, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

The systemic administration of interleukin-2 (IL-2) can lead to significant antitumor responses in some patients with metastatic cancer in whom standard therapy has failed. A limitation of this immunotherapy is the toxicity associated with IL-2 infusion. To assess toxicity, we determined aspartate aminotransferase (AST; EC 2.6.1.1), alanine aminotransferase (ALT; EC 2.6.1.2), gamma-glutamyltransferase (GGT; EC 2.3.2.2), lactate dehydrogenase (LD; EC 1.1.1.27), alkaline phosphatase (ALP; EC 3.1.3.1), creatine kinase (CK; EC 2.7.3.2), total bilirubin (TBI), direct bilirubin (DBI), creatinine, urea nitrogen, and C-reactive protein in serum from 21 patients before and during five consecutive days of IL-2 treatment. Ten patients were followed for an additional five days after the end of IL-2 therapy. The IL-2 infusion caused liver toxicity and prerenal azotemia, as evidenced by significant increases (P

Original languageEnglish (US)
Pages (from-to)431-434
Number of pages4
JournalClinical Chemistry
Volume36
Issue number3
StatePublished - Mar 1990
Externally publishedYes

Fingerprint

Interleukin-2
Toxicity
Neoplasms
Aspartate Aminotransferases
Alanine Transaminase
Bilirubin
Azotemia
gamma-Glutamyltransferase
Creatine Kinase
L-Lactate Dehydrogenase
Liver
C-Reactive Protein
Immunotherapy
Alkaline Phosphatase
Urea
Creatinine
Nitrogen
Therapeutics
Serum

Keywords

  • Chemotherapy
  • Liver and kidney toxicity

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Huang, C. M., Elin, R. J., Ruddel, M., Sliva, C., Lotze, M. T., & Rosenberg, S. A. (1990). Changes in laboratory results for cancer patients treated with interleukin-2. Clinical Chemistry, 36(3), 431-434.

Changes in laboratory results for cancer patients treated with interleukin-2. / Huang, C. M.; Elin, Ronald J.; Ruddel, Mark; Sliva, Clara; Lotze, Micahel T.; Rosenberg, Steven A.

In: Clinical Chemistry, Vol. 36, No. 3, 03.1990, p. 431-434.

Research output: Contribution to journalArticle

Huang, CM, Elin, RJ, Ruddel, M, Sliva, C, Lotze, MT & Rosenberg, SA 1990, 'Changes in laboratory results for cancer patients treated with interleukin-2', Clinical Chemistry, vol. 36, no. 3, pp. 431-434.
Huang CM, Elin RJ, Ruddel M, Sliva C, Lotze MT, Rosenberg SA. Changes in laboratory results for cancer patients treated with interleukin-2. Clinical Chemistry. 1990 Mar;36(3):431-434.
Huang, C. M. ; Elin, Ronald J. ; Ruddel, Mark ; Sliva, Clara ; Lotze, Micahel T. ; Rosenberg, Steven A. / Changes in laboratory results for cancer patients treated with interleukin-2. In: Clinical Chemistry. 1990 ; Vol. 36, No. 3. pp. 431-434.
@article{a6738229146a4dbb8d4be641f88d66e8,
title = "Changes in laboratory results for cancer patients treated with interleukin-2",
abstract = "The systemic administration of interleukin-2 (IL-2) can lead to significant antitumor responses in some patients with metastatic cancer in whom standard therapy has failed. A limitation of this immunotherapy is the toxicity associated with IL-2 infusion. To assess toxicity, we determined aspartate aminotransferase (AST; EC 2.6.1.1), alanine aminotransferase (ALT; EC 2.6.1.2), gamma-glutamyltransferase (GGT; EC 2.3.2.2), lactate dehydrogenase (LD; EC 1.1.1.27), alkaline phosphatase (ALP; EC 3.1.3.1), creatine kinase (CK; EC 2.7.3.2), total bilirubin (TBI), direct bilirubin (DBI), creatinine, urea nitrogen, and C-reactive protein in serum from 21 patients before and during five consecutive days of IL-2 treatment. Ten patients were followed for an additional five days after the end of IL-2 therapy. The IL-2 infusion caused liver toxicity and prerenal azotemia, as evidenced by significant increases (P",
keywords = "Chemotherapy, Liver and kidney toxicity",
author = "Huang, {C. M.} and Elin, {Ronald J.} and Mark Ruddel and Clara Sliva and Lotze, {Micahel T.} and Rosenberg, {Steven A.}",
year = "1990",
month = "3",
language = "English (US)",
volume = "36",
pages = "431--434",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "3",

}

TY - JOUR

T1 - Changes in laboratory results for cancer patients treated with interleukin-2

AU - Huang, C. M.

AU - Elin, Ronald J.

AU - Ruddel, Mark

AU - Sliva, Clara

AU - Lotze, Micahel T.

AU - Rosenberg, Steven A.

PY - 1990/3

Y1 - 1990/3

N2 - The systemic administration of interleukin-2 (IL-2) can lead to significant antitumor responses in some patients with metastatic cancer in whom standard therapy has failed. A limitation of this immunotherapy is the toxicity associated with IL-2 infusion. To assess toxicity, we determined aspartate aminotransferase (AST; EC 2.6.1.1), alanine aminotransferase (ALT; EC 2.6.1.2), gamma-glutamyltransferase (GGT; EC 2.3.2.2), lactate dehydrogenase (LD; EC 1.1.1.27), alkaline phosphatase (ALP; EC 3.1.3.1), creatine kinase (CK; EC 2.7.3.2), total bilirubin (TBI), direct bilirubin (DBI), creatinine, urea nitrogen, and C-reactive protein in serum from 21 patients before and during five consecutive days of IL-2 treatment. Ten patients were followed for an additional five days after the end of IL-2 therapy. The IL-2 infusion caused liver toxicity and prerenal azotemia, as evidenced by significant increases (P

AB - The systemic administration of interleukin-2 (IL-2) can lead to significant antitumor responses in some patients with metastatic cancer in whom standard therapy has failed. A limitation of this immunotherapy is the toxicity associated with IL-2 infusion. To assess toxicity, we determined aspartate aminotransferase (AST; EC 2.6.1.1), alanine aminotransferase (ALT; EC 2.6.1.2), gamma-glutamyltransferase (GGT; EC 2.3.2.2), lactate dehydrogenase (LD; EC 1.1.1.27), alkaline phosphatase (ALP; EC 3.1.3.1), creatine kinase (CK; EC 2.7.3.2), total bilirubin (TBI), direct bilirubin (DBI), creatinine, urea nitrogen, and C-reactive protein in serum from 21 patients before and during five consecutive days of IL-2 treatment. Ten patients were followed for an additional five days after the end of IL-2 therapy. The IL-2 infusion caused liver toxicity and prerenal azotemia, as evidenced by significant increases (P

KW - Chemotherapy

KW - Liver and kidney toxicity

UR - http://www.scopus.com/inward/record.url?scp=0025305806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025305806&partnerID=8YFLogxK

M3 - Article

C2 - 2311209

AN - SCOPUS:0025305806

VL - 36

SP - 431

EP - 434

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 3

ER -